Gynecomastia Linked to Increased Risk for Death

19 Jan 2024
www.drugs.com
Clinical Result
FRIDAY, Jan. 19, 2024 -- Men with gynecomastia have a increased risk for all-cause death, especially those with gynecomastia with a known preexisting risk factor, according to a study published online Jan. 16 in BMJ Open.
Elvira V. Bräuner, Ph.D., from Copenhagen University Hospital in Denmark, and colleagues conducted a nationwide register-based cohort study involving 23,429 men diagnosed with incident gynecomastia from Jan. 1, 1995, to June 30, 2021. Participants were age- and calendar-matched to randomly selected men without gynecomastia in a 1:5 ratio (117,145 controls).
Overall, 16,253 men with idiopathic gynecomastia and 7,176 with gynecomastia with a known preexisting risk factor were identified; of these, 6.7 and 20.9 percent, respectively, died during follow-up. The researchers found that the risk for all-cause death was significantly increased in men with gynecomastia in the entire cohort (hazard ratio [HR], 1.37; 95 percent confidence interval [CI], 1.31 to 1.43). The risk for death was highest in those diagnosed with gynecomastia who had a known preexisting risk factor (HR, 1.75; 95 percent CI, 1.64 to 1.86) compared with those with idiopathic gynecomastia (HR, 1.05; 95 percent CI, 0.98 to 1.13). Malignant neoplasms and circulatory, pulmonary, and gastrointestinal diseases were specific causes of increased death. A more than fivefold risk for death from liver disease was also identified (HR, 5.05; 95 percent CI, 3.97 to 6.42).
"These findings will hopefully stimulate more awareness among health care providers to potentially apply interventions that aid in alleviating underlying risk factors in males with this condition," the authors write.
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.